Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03189706 · ClinicalTrials.gov registry record · Early Phase 1
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
A Early Phase 1 study of Neuroblastoma (NB), sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT03189706: Active Early Phase 1 study of Neuroblastoma (NB), sponsored by Memorial Sloan Kettering Cancer Center.
NCT03189706 is a Early Phase 1 study of Neuroblastoma (NB) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 48 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03189706, a Early Phase 1 study of Neuroblastoma (NB), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether an experimental drug called Hu3F8 can be given with the chemotherapy drugs irinotecan and temozolomide and another drug called GM-CSF. The investigators want to find out if this combination is safe and what effect it has on the participant and the disease.
Primary Outcome
The regimen will be considered safe if there are no toxicities requiring discontinuation of therapy in at least 9/10 patients during the first two cycles.
Conditions Studied
Interventions
- DRUG Irinotecan
- DRUG GM-CSF
- DRUG temozolomide
- BIOLOGICAL Hu3F8
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-06-12 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
What the registry record for NCT03189706 still lists
NCT03189706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Neuroblastoma (NB) appearing as the primary indexed condition, and to 4 interventions - of which Irinotecan is the first listed.
NCT03189706 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03189706 about?
NCT03189706 is a clinical study titled "Study of Chemoimmunotherapy for High-Risk Neuroblastoma". The purpose of this study is to find out whether an experimental drug called Hu3F8 can be given with the chemotherapy drugs irinotecan and temozolomide and another drug called GM-CSF. The investigators want to find out if this combination is safe and what effect it has on the participant and the dis...
What is the current status of trial NCT03189706?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2017-06-12. Estimated completion is 2026-06.
What conditions does trial NCT03189706 study?
This clinical trial studies the following conditions: Neuroblastoma (NB).
What interventions are being tested in trial NCT03189706?
The interventions under investigation include: Irinotecan (DRUG), GM-CSF (DRUG), temozolomide (DRUG), Hu3F8 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03189706?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03189706 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03189706's enrollment target sits among peer trials
48 541st of 2000 higher than 1,439 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI